# reload+after+2024-01-19 21:45:39.737290
address1§103 Montgomery Street
address2§Suite 150 The Presidio of San Francisco
city§San Francisco
state§CA
zip§94129
country§United States
phone§858 299 4699
website§https://www.kinnate.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
fullTimeEmployees§84
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Nima  Farzan M.B.A.', 'age': 47, 'title': 'President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 891954, 'exercisedValue': 0, 'unexercisedValue': 3230306}, {'maxAge': 1, 'name': 'Ms. Neha  Krishnamohan', 'age': 36, 'title': 'CFO, Principal Accounting Officer and Executive VP of Corporate Development', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 548950, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark A. Meltz', 'age': 49, 'title': 'COO, General Counsel, Treasurer & Secretary', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 671864, 'exercisedValue': 0, 'unexercisedValue': 938185}, {'maxAge': 1, 'name': 'Dr. Richard Thomas Williams MBBS, Ph.D.', 'age': 54, 'title': 'Chief Medical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert  Kania Ph.D.', 'title': 'Senior Vice President of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§6
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.333
currency§USD
dateShortInterest§1702598400
forwardEps§-1.36
exchange§NMS
quoteType§EQUITY
shortName§Kinnate Biopharma Inc.
longName§Kinnate Biopharma Inc.
firstTradeDateEpochUtc§1607005800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§855105e2-a924-3604-af58-829eb0836a45
gmtOffSetMilliseconds§-18000000
targetHighPrice§4.0
targetLowPrice§1.5
targetMeanPrice§2.7
targetMedianPrice§2.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§10.624
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
